Abstract
Neisseria meningitidis (the meningococcus) is a member of the normal nasopharyngeal microbiome in healthy individuals, but can cause septicemia and meningitis in susceptible individuals. In this chapter we provide an overview of the disease caused by N. meningitidis and the schemes used to type the meningococcus. We also review the adhesions, virulence factors, and phase variable genes that enable it to successfully colonize the human host. Finally, we outline the history and current status of meningococcal vaccines and highlight the importance of continued molecular investigation of the epidemiology and the structural analysis of the antigens of this pathogen to aid future vaccine development.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Liu G, Tang CM, Exley RM (2015) Non-pathogenic Neisseria: members of an abundant, multi-habitat, diverse genus. Microbiology 161:1297–1312
Blakebrough IS, Greenwood BM, Whittle HC, Bradley AK, Gilles HM (1982) The epidemiology of infections due to Neisseria meningitidis and Neisseria lactamica in a northern Nigerian community. J Infect Dis 146:626–637
Winstanley FP, Blackwell CC, Weir DM (1985) Factors influencing host susceptibility to meningococcal disease. Biomed Pharmacother 39:167–170
Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM (2001) Medical progress: meningococcal disease. N Engl J Med 344:1378–1388
Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, Kaczmarski E, Rajput K, Ramsay M, Christie D (2012) Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 11:774–783
Vyse A, Anonychuk A, Jakel A, Wieffer H, Nadel S (2013) The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti-Infect Ther 11:597–604
Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, Wenger JD, Stephens DS (1997) Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci U S A 94:271–276
Liu TY, Gotschlich EC, Jonssen EK, Wysocki JR (1971) Studies on the meningococcal polysaccharides. I. Composition and chemical properties of the group A polysaccharide. J Biol Chem 246:2849–2858
Bundle DR, Jennings HJ, Kenny CP (1973) An improved procedure for the isolation of meningococcal, polysaccharide antigens, and the structural determination of the antigen from serogroup X. Carbohydr Res 26:268–270
Maiden MCJ, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, Zhang Q, Zhou JJ, Zurth K, Caugant DA, Feavers IM, Achtman M, Spratt BG (1998) Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95:3140–3145
Maiden MC (2006) Multilocus sequence typing of bacteria. Annu Rev Microbiol 60:561–588
Brehony C, Jolley KA, Maiden MC (2007) Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev 31:15–26
Maiden MC, Harrison OB (2016) Population and functional genomics of Neisseria revealed with gene-by-gene approaches. J Clin Microbiol 54:1949–1955
Bratcher HB, Corton C, Jolley KA, Parkhill J, Maiden MCJ (2014) A gene-by-gene population genomics platform: de novo assembly, annotation and genealogical analysis of 108 representative Neisseria meningitidis genomes. BMC Genomics 15:1138
Merz AJ, So M (2000) Interactions of pathogenic neisseriae with epithelial cell membranes. Annu Rev Cell Dev Biol 16:423–457
Capecchi B, Adu-Bobie J, Di Marcello F, Ciucchi L, Masignani V, Taddei A, Rappuoli R, Pizza M, Arico B (2005) Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 55:687–698
Martin D, Cadieux N, Hamel J, Brodeur BR (1997) Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 185:1173–1183
Turner DP, Marietou AG, Johnston L, Ho KK, Rogers AJ, Wooldridge KG, Ala’Aldeen DA (2006) Characterization of MspA, an immunogenic autotransporter protein that mediates adhesion to epithelial and endothelial cells in Neisseria meningitidis. Infect Immun 74:2957–2964
Griffiths NJ, Hill DJ, Borodina E, Sessions RB, Devos NI, Feron CM, Poolman JT, Virji M (2011) Meningococcal surface fibril (Msf) binds to activated vitronectin and inhibits the terminal complement pathway to increase serum resistance. Mol Microbiol 82:1129–1149
Stephens DS, Hoffman LH, McGee ZA (1983) Interaction of Neisseria meningitidis with human nasopharyngeal mucosa: attachment and entry into columnar epithelial cells. J Infect Dis 148:369–376
Virji M, Makepeace K, Moxon ER (1994) Distinct mechanisms of interactions of Opc-expressing meningococci at apical and basolateral surfaces of human endothelial cells; the role of integrins in apical interactions. Mol Microbiol 14:173–184
Sutherland TC, Quattroni P, Exley RM, Tang CM (2010) Transcellular passage of Neisseria meningitidis across a polarized respiratory epithelium. Infect Immun 78:3832–3847
Berry JL, Pelicic V (2015) Exceptionally widespread nanomachines composed of type IV pilins: the prokaryotic Swiss Army knives. FEMS Microbiol Rev 39:134–154
Carbonnelle E, Helaine S, Nassif X, Pelicic V (2006) A systematic genetic analysis in Neisseria meningitidis defines the Pil proteins required for assembly, functionality, stabilization and export of type IV pili. Mol Microbiol 61:1510–1522
Kolappan S, Coureuil M, Yu X, Nassif X, Egelman EH, Craig L (2016) Structure of the Neisseria meningitidis type IV pilus. Nat Commun 7:13015
Virji M, Heckels JE (1983) Antigenic cross-reactivity of Neisseria pili: investigations with type- and species-specific monoclonal antibodies. J Gen Microbiol 129:2761–2768
Wormann ME, Horien CL, Bennett JS, Jolley KA, Maiden MC, Tang CM, Aho EL, Exley RM (2014) Sequence, distribution and chromosomal context of class I and class II pilin genes of Neisseria meningitidis identified in whole genome sequences. BMC Genomics 15:253
Haas R, Meyer TF (1986) The repertoire of silent pilus genes in Neisseria gonorrhoeae: evidence for gene conversion. Cell 44:107–115
Gault J, Ferber M, Machata S, Imhaus AF, Malosse C, Charles-Orszag A, Millien C, Bouvier G, Bardiaux B, Pehau-Arnaudet G, Klinge K, Podglajen I, Ploy MC, Seifert HS, Nilges M, Chamot-Rooke J, Dumenil G (2015) Neisseria meningitidis type iv pili composed of sequence invariable pilins are masked by multisite glycosylation. PLoS Pathog 11:e1005162
Chen I, Dubnau D (2004) DNA uptake during bacterial transformation. Nat Rev Microbiol 2:241–249
Maiden MC (2008) Population genomics: diversity and virulence in the Neisseria. Curr Opin Microbiol 11:467–471
Cehovin A, Simpson PJ, McDowell MA, Brown DR, Noschese R, Pallett M, Brady J, Baldwin GS, Lea SM, Matthews SJ, Pelicic V (2013) Specific DNA recognition mediated by a type IV pilin. Proc Natl Acad Sci U S A 110:3065–3070
Berry J-L, Cehovin A, McDowell MA, Lea SM, Pelicic V (2013) Functional analysis of the interdependence between DNA uptake sequence and its cognate ComP receptor during natural transformation in Neisseria species. PLoS Genet 9:e1004014
Virji M, Makepeace K, Ferguson DJ, Achtman M, Moxon ER (1993) Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells. Mol Microbiol 10:499–510
Stern A, Brown M, Nickel P, Meyer TF (1986) Opacity genes in Neisseria gonorrhoeae: control of phase and antigenic variation. Cell 47:61–71
Sadarangani M, Pollard AJ, Gray-Owen SD (2011) Opa proteins and CEACAMs: pathways of immune engagement for pathogenic Neisseria. FEMS Microbiol Rev 35:498–514
Malorny B, Morelli G, Kusecek B, Kolberg J, Achtman M (1998) Sequence diversity, predicted two-dimensional protein structure, and epitope mapping of neisserial Opa proteins. J Bacteriol 180:1323–1330
Fox DA, Larsson P, Lo RH, Kroncke BM, Kasson PM, Columbus L (2014) Structure of the Neisserial outer membrane protein Opa(60): loop flexibility essential to receptor recognition and bacterial engulfment. J Am Chem Soc 136:9938–9946
Leyton DL, Rossiter AE, Henderson IR (2012) From self sufficiency to dependence: mechanisms and factors important for autotransporter biogenesis. Nat Rev Microbiol 10:213–225
Hadi HA, Wooldridge KG, Robinson K, Ala’Aldeen DA (2001) Identification and characterization of App: an immunogenic autotransporter protein of Neisseria meningitidis. Mol Microbiol 41:611–623
Turner DP, Wooldridge KG, Ala’Aldeen DA (2002) Autotransported serine protease A of Neisseria meningitidis: an immunogenic, surface-exposed outer membrane, and secreted protein. Infect Immun 70:4447–4461
Rawlings ND, Barrett AJ, Bateman A (2012) MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 40:D343–D350
Hill DJ, Griffiths NJ, Borodina E, Andreae CA, Sessions RB, Virji M (2015) Identification and therapeutic potential of a vitronectin binding region of meningococcal msf. PLoS One 10:e0124133
Vidarsson G, Overbeeke N, Stemerding AM, van den Dobbelsteen G, van Ulsen P, van der Ley P, Kilian M, van de Winkel JG (2005) Working mechanism of immunoglobulin A1 (IgA1) protease: cleavage of IgA1 antibody to Neisseria meningitidis PorA requires de novo synthesis of IgA1 protease. Infect Immun 73:6721–6726
Roussel-Jazede V, Arenas J, Langereis JD, Tommassen J, van Ulsen P (2014) Variable processing of the IgA protease autotransporter at the cell surface of Neisseria meningitidis. Microbiology 160:2421–2431
Arenas J, Nijland R, Rodriguez Francisco J, Bosma Tom NP, Tommassen J (2012) Involvement of three meningococcal surface-exposed proteins, the heparin-binding protein NhbA, the α-peptide of IgA protease and the autotransporter protease NalP, in initiation of biofilm formation. Mol Microbiol 87:254–268
van Ulsen P, van Alphen L, ten Hove J, Fransen F, van der Ley P, Tommassen J (2003) A Neisserial autotransporter NalP modulating the processing of other autotransporters. Mol Microbiol 50:1017–1030
Roussel-Jazede V, Grijpstra J, van Dam V, Tommassen J, van Ulsen P (2013) Lipidation of the autotransporter NalP of Neisseria meningitidis is required for its function in the release of cell-surface-exposed proteins. Microbiology 159:286–295
Besbes A, Le Goff S, Antunes A, Terrade A, Hong E, Giorgini D, Taha MK, Deghmane AE (2015) Hyperinvasive Meningococci induce intra-nuclear cleavage of the NF-kappaB Protein p65/RelA by meningococcal IgA protease. PLoS Pathog 11:e1005078
Serruto D, Adu-Bobie J, Scarselli M, Veggi D, Pizza M, Rappuoli R, Arico B (2003) Neisseria meningitidis App, a new adhesin with autocatalytic serine protease activity. Mol Microbiol 48:323–334
Khairalla AS, Omer SA, Mahdavi J, Aslam A, Dufailu OA, Self T, Jonsson AB, Georg M, Sjolinder H, Royer PJ, Martinez-Pomares L, Ghaemmaghami AM, Wooldridge KG, Oldfield NJ, Ala’Aldeen DA (2015) Nuclear trafficking, histone cleavage and induction of apoptosis by the meningococcal App and MspA autotransporters. Cell Microbiol 17:1008–1020
Arenas J, Paganelli FL, Rodríguez-Castaño P, Cano-Crespo S, van der Ende A, van Putten JPM, Tommassen J (2016) Expression of the gene for autotransporter AutB of Neisseria meningitidis Affects biofilm formation and epithelial transmigration. Front Cell Infect Microbiol 6:162
Arenas J, Cano S, Nijland R, van Dongen V, Rutten L, van der Ende A, Tommassen J (2015) The meningococcal autotransporter AutA is implicated in autoaggregation and biofilm formation. Environ Microbiol 17:1321–1337
van Ulsen P, Adler B, Fassler P, Gilbert M, van Schilfgaarde M, van der Ley P, van Alphen L, Tommassen J (2006) A novel phase-variable autotransporter serine protease, AusI, of Neisseria meningitidis. Microbes Infect 8:2088–2097
Serruto D, Spadafina T, Ciucchi L, Lewis LA, Ram S, Tontini M, Santini L, Biolchi A, Seib KL, Giuliani MM, Donnelly JJ, Berti F, Savino S, Scarselli M, Costantino P, Kroll JS, O’Dwyer C, Qiu J, Plaut AG, Moxon R, Rappuoli R, Pizza M, Arico B (2010) Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A 107:3770–3775
Del Tordello E, Vacca I, Ram S, Rappuoli R, Serruto D (2014) Neisseria meningitidis NalP cleaves human complement C3, facilitating degradation of C3b and survival in human serum. Proc Natl Acad Sci 111:427
Echenique-Rivera H, Muzzi A, Del Tordello E, Seib KL, Francois P, Rappuoli R, Pizza M, Serruto D (2011) Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival. PLoS Pathog 7:e1002027
Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, Galeotti CL, Luzzi E, Manetti R, Marchetti E, Mora M, Nuti S, Ratti G, Santini L, Savino S, Scarselli M, Storni E, Zuo P, Broeker M, Hundt E, Knapp B, Blair E, Mason T, Tettelin H, Hood DW, Jeffries AC, Saunders NJ, Granoff DM, Venter JC, Moxon ER, Grandi G, Rappuoli R (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287:1816–1820
Litt DJ, Savino S, Beddek A, Comanducci M, Sandiford C, Stevens J, Levin M, Ison C, Pizza M, Rappuoli R, Kroll JS (2004) Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis 190:1488–1497
Sjölinder M, Altenbacher G, Hagner M, Sun W, Schedin-Weiss S, Sjölinder H (2012) Meningococcal outer membrane protein NhhA triggers apoptosis in macrophages. PLoS One 7:e29586
Wang X, Sjölinder M, Gao Y, Wan Y, Sjölinder H (2016) Immune homeostatic macrophages programmed by the bacterial surface protein NhhA potentiate nasopharyngeal carriage of Neisseria meningitidis. MBio 7:e01670–e01615
Andreae CA, Sessions RB, Virji M, Hill DJ (2018) Bioinformatic analysis of meningococcal Msf and Opc to inform vaccine antigen design. PLoS One 13:e0193940
Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, Carannante A, Deghmane AE, Fazio C, Frosch M, Frosi G, Gilchrist S, Giuliani MM, Hong E, Ledroit M, Lovaglio PG, Lucidarme J, Musilek M, Muzzi A, Oksnes J, Rigat F, Orlandi L, Stella M, Thompson D, Pizza M, Rappuoli R, Serruto D, Comanducci M, Boccadifuoco G, Donnelly JJ, Medini D, Borrow R (2013) Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 13:416–425
Fagnocchi L, Biolchi A, Ferlicca F, Boccadifuoco G, Brunelli B, Brier S, Norais N, Chiarot E, Bensi G, Kroll JS, Pizza M, Donnelly J, Giuliani MM, Delany I (2013) Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine. Infect Immun 81:560–569
Green LR, Lucidarme J, Dave N, Chan H, Clark S, Borrow R, Bayliss CD (2018) Phase variation of NadA in invasive Neisseria meningitidis isolates impacts on coverage estimates for 4C-MenB, a MenB vaccine. J Clin Microbiol 56:e00204-18
Malito E, Biancucci M, Faleri A, Ferlenghi I, Scarselli M, Maruggi G, Lo Surdo P, Veggi D, Liguori A, Santini L, Bertoldi I, Petracca R, Marchi S, Romagnoli G, Cartocci E, Vercellino I, Savino S, Spraggon G, Norais N, Pizza M, Rappuoli R, Masignani V, Bottomley MJ (2014) Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody. Proc Natl Acad Sci U S A 111:17128–17133
Rotman E, Seifert HS (2014) The genetics of Neisseria species. Annu Rev Genet 48:405–431
Moxon R, Bayliss C, Hood D (2006) Bacterial contingency loci: the role of simple sequence DNA repeats in bacterial adaptation. Annu Rev Genet 40:307–333
McGuinness B, Barlow AK, Clarke IN, Farley JE, Anilionis A, Poolman JT, Heckels JE (1990) Deduced amino acid sequences of class 1 protein (PorA) from three strains of Neisseria meningitidis. Synthetic peptides define the epitopes responsible for serosubtype specificity. J Exp Med 171:1871–1882
Lewis LA, Gipson M, Hartman K, Ownbey T, Vaughn J, Dyer DW (1999) Phase variation of HpuAB and HmbR, two distinct haemoglobin receptors of Neisseria meningitidis DNM2. Mol Microbiol 32:977–989
Srikhanta YN, Fox KL, Jennings MP (2010) The phasevarion: phase variation of type III DNA methyltransferases controls coordinated switching in multiple genes. Nat Rev Microbiol 8:196
Tauseef I, Harrison OB, Wooldridge KG, Feavers IM, Neal KR, Gray SJ, Kriz P, Turner DP, Ala’Aldeen DA, Maiden MC, Bayliss CD (2011) Influence of the combination and phase variation status of the haemoglobin receptors HmbR and HpuAB on meningococcal virulence. Microbiology 157:1446–1456
Perkins-Balding D, Ratliff-Griffin M, Stojiljkovic I (2004) Iron transport systems in Neisseria meningitidis. Microbiol Mol Biol Rev 68:154–171
Stojiljkovic I, Hwa V, de Saint Martin L, O’Gaora P, Nassif X, Heffron F, So M (1995) The Neisseria meningitidis haemoglobin receptor: its role in iron utilization and virulence. Mol Microbiol 15:531–541
Sevestre J, Diene SM, Aouiti-Trabelsi M, Deghmane A-E, Tournier I, François P, Caron F, Taha M-K (2018) Differential expression of hemoglobin receptor, HmbR, between carriage and invasive isolates of Neisseria meningitidis contributes to virulence: lessons from a clonal outbreak. Virulence 9:923–929
Lucidarme J, Findlow J, Chan H, Feavers IM, Gray SJ, Kaczmarski EB, Parkhill J, Bai X, Borrow R, Bayliss CD (2013) The distribution and ‘in vivo’ phase variation status of haemoglobin receptors in invasive meningococcal serogroup B disease: genotypic and phenotypic analysis. PLoS One 8:e76932
Bidmos FA, Chan H, Praekelt U, Tauseef I, Ali YM, Kaczmarski EB, Feavers I, Bayliss CD (2015) Investigation into the antigenic properties and contributions to growth in blood of the meningococcal haemoglobin receptors, HpuAB and HmbR. PLoS One 10:e0133855
Borud B, Barnes GK, Brynildsrud OB, Fritzsonn E, Caugant DA (2018) Genotypic and phenotypic characterization of the O-linked protein glycosylation system reveals high glycan diversity in paired meningococcal carriage isolates. J Bacteriol 200:e00794-17
Barnes GK, Brynildsrud OB, Borud B, Workalemahu B, Kristiansen PA, Beyene D, Aseffa A, Caugant DA (2017) Whole genome sequencing reveals within-host genetic changes in paired meningococcal carriage isolates from Ethiopia. BMC Genomics 18:407
Seib KL, Pigozzi E, Muzzi A, Gawthorne JA, Delany I, Jennings MP, Rappuoli R (2011) A novel epigenetic regulator associated with the hypervirulent Neisseria meningitidis clonal complex 41/44. FASEB J 25:3622–3633
Srikhanta YN, Dowideit SJ, Edwards JL, Falsetta ML, Wu HJ, Harrison OB, Fox KL, Seib KL, Maguire TL, Wang AH, Maiden MC, Grimmond SM, Apicella MA, Jennings MP (2009) Phasevarions mediate random switching of gene expression in pathogenic Neisseria. PLoS Pathog 5:e1000400
Jen FEC, Seib KL, Jennings MP (2014) Phasevarions mediate epigenetic regulation of antimicrobial susceptibility in Neisseria meningitidis. Antimicrob Agents Chemother 58:4219–4221
Clark TA, Murray IA, Morgan RD, Kislyuk AO, Spittle KE, Boitano M, Fomenkov A, Roberts RJ, Korlach J (2012) Characterization of DNA methyltransferase specificities using single-molecule, real-time DNA sequencing. Nucleic Acids Res 40:e29
Seib KL, Jen FEC, Tan A, Scott AL, Kumar R, Power PM, Chen L-T, Wu H-J, Wang AHJ, Hill D M C, Luyten YA, Morgan RD, Roberts RJ, Maiden M C J, Boitano M, Clark TA, Korlach J, Rao DN, Jennings MP (2015) Specificity of the ModA11, ModA12 and ModD1 epigenetic regulator N(6)-adenine DNA methyltransferases of Neisseria meningitidis. Nucleic Acids Res 43:4150–4162
Davis DJ (1907) Studies in Meningococcus infections. J Infect Dis 4:558–581
Riding D, Corkill NL (1932) Prophylactic vaccination in epidemic meningococcal meningitis. J Hyg (Lond) 32:258–267
Goldschneider I, Gotschlich EC, Artenstein MS (1969) Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129:1307–1326
Gotschlich EC, Goldschneider I, Artenstein MS (1969) Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 129:1367–1384
Jennings HJ, Lugowski C (1981) Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol 127:1011–1018
Cruse JM, Lewis RE Jr (1989) Contemporary trends in conjugate vaccine development. Contrib Microbiol Immunol 10:1–10
Balmer P, Borrow R, Miller E (2002) Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 51:717–722
Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, Walker AM, Evans MR, Kroll JS, Neal KR, Ala’aldeen DA, Crook DW, Cann K, Harrison S, Cunningham R, Baxter D, Kaczmarski E, Maclennan J, Cameron JC, Stuart JM (2008) Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 197:737–743
Bartoloni A, Norelli F, Ceccarini C, Rappuoli R, Costantino P (1995) Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide. Vaccine 13:463–470
Frasch CE, Parkes L, McNelis RM, Gotschlich EC (1976) Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model. J Exp Med 144:319–329
Sotolongo F, Campa C, Casanueva V, Fajardo EM, Cuevas IE, Gonzalez N (2007) Cuban meningococcal BC vaccine: experiences & contributions from 20 years of application. MEDICC Rev 9:16–22
Bjune G, Høiby EA, Grønnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nøkleby H, Rosenqvist E (1991) Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093–1096
Oster P, Lennon D, O’Hallahan J, Mulholland K, Reid S, Martin D (2005) MeNZB™: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23:2191–2196
Holst J, Feiring B, Naess LM, Norheim G, Kristiansen P, Hoiby EA, Bryn K, Oster P, Costantino P, Taha MK, Alonso JM, Caugant DA, Wedege E, Aaberge IS, Rappuoli R, Rosenqvist E (2005) The concept of “tailor-made”, protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 23:2202–2205
van den Dobbelsteen G, van Dijken H, Hamstra HJ, Ummels R, van Alphen L, van der Ley P. From HexaMen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine. In: Paper presented at the international pathogenic Neisseria conference, Milwaukee, WI
Luijkx TA, van Dijken H, Hamstra HJ, Kuipers B, van der Ley P, van Alphen L, van den Dobbelsteen G (2003) Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form. Infect Immun 71:6367–6371
Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, Cartocci E, Ciucchi L, Di Marcello F, Ferlicca F, Galli B, Luzzi E, Masignani V, Serruto D, Veggi D, Contorni M, Morandi M, Bartalesi A, Cinotti V, Mannucci D, Titta F, Ovidi E, Welsch JA, Granoff D, Rappuoli R, Pizza M (2006) A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103:10834–10839
Green LR, Eiden J, Hao L, Jones T, Perez J, McNeil LK, Jansen KU, Anderson AS (2016) Approach to the discovery, development, and evaluation of a novel Neisseria meningitidis serogroup b vaccine. Methods Mol Biol 1403:445–469
Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, DaSilva I, Mack M, Zhao XJ, Pride MW, Andrew L, Murphy E, Hagen M, French R, Arora A, Jones TR, Jansen KU, Zlotnick GW, Anderson AS (2010) Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28:6086–6093
Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, Deghmane AE, Kriz P, Musilek M, Kalmusova J, Caugant DA, Alvestad T, Mayer LW, Sacchi CT, Wang X, Martin D, von Gottberg A, du Plessis M, Klugman KP, Anderson AS, Jansen KU, Zlotnick GW, Hoiseth SK (2009) Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 200:379–389
Schneider MC, Prosser BE, Caesar JJ, Kugelberg E, Li S, Zhang Q, Quoraishi S, Lovett JE, Deane JE, Sim RB, Roversi P, Johnson S, Tang CM, Lea SM (2009) Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458:890–893
Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, Granoff DM (2011) A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 186:3606–3614
Johnson S, Tan L, van der Veen S, Caesar J, Goicoechea De Jorge E, Harding RJ, Bai X, Exley RM, Ward PN, Ruivo N, Trivedi K, Cumber E, Jones R, Newham L, Staunton D, Ufret-Vincenty R, Borrow R, Pickering MC, Lea SM, Tang CM (2012) Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules. PLoS Pathog 8:e1002981
Hollingshead S, Jongerius I, Exley RM, Johnson S, Lea SM, Tang CM (2018) Structure-based design of chimeric antigens for multivalent protein vaccines. Nat Commun 9:1051
Koeberling O, Seubert A, Santos G, Colaprico A, Ugozzoli M, Donnelly J, Granoff DM (2011) Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine 29(29–30):4728–4734
Wu X, Li K, Xie M, Yu M, Tang S, Li Z, Hu S (2018) Construction and protective immunogenicity of DNA vaccine pNMB0315 against serogroup B. Mol Med Rep 17(2):3178–3185
Trotter CL, Lingani C, Fernandez K, Cooper LV, Bita A, Tevi-Benissan C, Ronveaux O, Preziosi MP, Stuart JM (2017) Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance data. Lancet Infect Dis 17:867–872
LaForce FM, Djingarey M, Viviani S, Preziosi MP (2018) Successful African introduction of a new Group A meningococcal conjugate vaccine: future challenges and next steps. Hum Vaccin Immunother 14:1098–1102
Epidemic meningitis control in countries of the African meningitis belt, 2016. Wkly Epidemiol Rec 2017;92:145-154.
Diomandé FVK, Djingarey MH, Daugla DM, Novak RT, Kristiansen PA, Collard J-M, Gamougam K, Kandolo D, Mbakuliyemo N, Mayer L, Stuart J, Clark T, Tevi-Benissan C, Perea WA, Preziosi M-P, Marc LaForce F, Caugant D, Messonnier N, Walker O, Greenwood B (2015) Public health impact after the introduction of PsA-TT: the first 4 years. Clin Infect Dis 61:S467–S472
Mustapha MM, Harrison LH (2018) Vaccine prevention of meningococcal disease in Africa: major advances, remaining challenges. Hum Vaccin Immunother 14:1107–1115
Chilukuri SR, Reddy P, Avalaskar N, Mallya A, Pisal S, Dhere RM (2014) Process development and immunogenicity studies on a serogroup ‘X’ Meningococcal polysaccharide conjugate vaccine. Biologicals 42:160–168
Davila S, Wright VJ, Khor CC, Sim KS, Binder A, Breunis WB, Inwald D, Nadel S, Betts H, Carrol ED, de Groot R, Hermans PW, Hazelzet J, Emonts M, Lim CC, Kuijpers TW, Martinon-Torres F, Salas A, Zenz W, Levin M, Hibberd ML (2010) Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet 42:772–776
Caesar JJ, Lavender H, Ward PN, Exley RM, Eaton J, Chittock E, Malik TH, Goiecoechea De Jorge E, Pickering MC, Tang CM, Lea SM (2014) Competition between antagonistic complement factors for a single protein on N. meningitidis rules disease susceptibility. elife 3:04008
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Hollingshead, S., Tang, C.M. (2019). An Overview of Neisseria meningitidis. In: Seib, K., Peak, I. (eds) Neisseria meningitidis. Methods in Molecular Biology, vol 1969. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-9202-7_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9202-7_1
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-9201-0
Online ISBN: 978-1-4939-9202-7
eBook Packages: Springer Protocols